Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × osimertinib × 30 days × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 8 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Stage II-IIIB Non-small Cell Lung Carcinoma 1 Squamous Cell Carcinoma of Head and Neck 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡